UCLA researchers in the Departments of Molecular and Medical Pharmacology and Medicine have developed a novel method to treat melanoma.
Immune checkpoint blockade immunotherapy with anti-PD1 antibody is the preferred treatment for patients with metastatic melanoma that has resisted other therapies. However, there remains a subset of patients that does not respond to or relapses following this therapeutic strategy, as de-differentiation of melanoma cells is known to increase resistance to conventional immunotherapies. So far there is no therapy specifically tailored to target these immunotherapy-resistant de-differentiated melanoma cells.
Researchers at UCLA have developed a method to treat melanoma that resists conventional immune checkpoint blockade immunotherapy by using ferroptosis-inducing drugs. Ferroptosis is a type of cell death resulting from accumulation of reactive oxygen species that degrade lipids in the cell membrane. De-differentiating cells, such as the immunotherapy-resistant or kinase inhibitor-resistant melanoma, are highly susceptible to ferroptosis. Combination treatment with ferroptosis-inducing agents can be a valuable, new synergistic approach for overcoming resistance to melanoma therapy.
|Patent Cooperation Treaty||Published Application||2019006005||01/03/2019||2017-879|
Additional Patent Pending
melanoma resistant ferroptosis skin cancer drugs immunotherapy PD1 CTLA4 combination immune checkpoint blockade, MAP kinase pathway, MAPK, BRAF inhibitors, MEK inhibitors